drugset
drugset / Trial / NCT05555316

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

NCT05555316 ↗

Phase 2 Unknown 46 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

To explore the objective effectiveness and safety of TACE combined with Lenvatinib in the treatment of advanced liver cancer. After successful down-stage, radical microwave ablation was further performed.

Timeline

Start
2019-11-10
Primary completion
2023-01
Completion
2023-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule 8 mg Oral
Subject Lenvatinib Small molecule 12 mg Oral

Indications

liver cancer